{
    "clinical_study": {
        "@rank": "95606", 
        "arm_group": [
            {
                "arm_group_label": "Beclomethasone dipropionate (BDP) nasal aerosol", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo Nasal Aerosol", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the effect of 6 weeks of treatment with\n      beclomethasone dipropionate (BDP) nasal aerosol versus placebo on HPA-axis function, as\n      assessed by 24-hour serum cortisol weighted mean, and to evaluate the safety and\n      tolerability of BDP nasal aerosol, in subjects 6 to 11 years of age with perennial allergic\n      rhinitis."
        }, 
        "brief_title": "Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR)", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Allergic Rhinitis", 
        "condition_browse": {
            "mesh_term": [
                "Rhinitis", 
                "Rhinitis, Allergic, Perennial"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent/(assent - if applicable)\n\n          -  Male or female subjects 6-11 years of age\n\n          -  General good health\n\n          -  A documented history of PAR to a relevant perennial allergen for a minimum of 12\n             months\n\n          -  Other criteria apply\n\n        Exclusion Criteria:\n\n          -  Pregnancy, nursing, or plans to become pregnant or donate gametes\n\n          -  Participation in any investigational drug study within the 30 days preceding the\n             Screening Visit 1 (SV1)\n\n          -  Previous participation in a BDP nasal aerosol study as a randomized subject\n\n          -  A known hypersensitivity to any corticosteroid or any of the excipients in the study\n             medication formulation\n\n          -  History of physical findings of nasal pathology, including nasal polyps or other\n             clinically significant respiratory tract malformations\n\n          -  History of a respiratory infection or disorder within the 14 days preceding the\n             Screening Visit 1 (SV1)\n\n          -  Use of any prohibited concomitant medications within the prescribed (per protocol)\n             withdrawal periods prior to the Screening Visit 1 (SV1)\n\n          -  Other criteria apply\n\n          -  Current smoker or current user of tobacco products at any time during the study;\n             history of smoking or use of tobacco products within the past year"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "11 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "99", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01697956", 
            "org_study_id": "BDP-AR-307"
        }, 
        "intervention": [
            {
                "arm_group_label": "Beclomethasone dipropionate (BDP) nasal aerosol", 
                "description": "Dose: BDP 80 mcg/day (40 mcg/spray, 1 spray/nostril, once daily - total 2 sprays/day)", 
                "intervention_name": "Beclomethasone dipropionate (BDP) nasal aerosol", 
                "intervention_type": "Drug", 
                "other_name": "QNASL (TM)"
            }, 
            {
                "arm_group_label": "Placebo Nasal Aerosol", 
                "description": "Dose: 1 spray/nostril, once daily - total 2 sprays/day", 
                "intervention_name": "Placebo Nasal Aerosol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Beclomethasone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Pediatric Subjects", 
        "lastchanged_date": "May 8, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Long Beach", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Teva Investigational Site 10305"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockbridge", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Teva Investigational Site 10304"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Plymouth", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }, 
                    "name": "Teva Investigational Site 10300"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Normal", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "Teva Investigational Site 10302"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Braunfels", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Teva Investigational Site 10301"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Teva Investigational Site 10303"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Study Designed to Investigate the Effects of BDP Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal (HPA)-Axis in Pediatric Subjects (6 to 11 Years of Age) With Perennial Allergic Rhinitis (PAR)", 
        "overall_official": {
            "affiliation": "Teva Branded Pharmaceutical Products, R&D Inc.", 
            "last_name": "Sudeesh K Tantry, Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is the 24-hour serum cortisol weighted mean for BDP nasal aerosol and placebo after forty two (42) days of treatment.", 
            "measure": "24-Hour serum Cortisol weighted mean after 42 days of treatment", 
            "safety_issue": "No", 
            "time_frame": "Baseline to 42 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01697956"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Teva Pharmaceutical Industries", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Teva Pharmaceutical Industries", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}